ESK-001 Dose Level 5 for Plaque Psoriasis

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Plaque PsoriasisESK-001 - Drug
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.

Eligible Conditions
  • Plaque Psoriasis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 12 weeks

12 weeks
Heart rate
Psoriasis
To compare the Psoriasis Area and Severity Index (PASI-75) between doses of ESK-001 and placebo
8 weeks
To characterize the pharmacokinetics (PK) of ESK-001 (Cmax)
To characterize the pharmacokinetics (PK) of ESK-001 (Ctrough)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

6 Treatment Groups

ESK-001 Dose Level 5
1 of 6
ESK-001 Dose Level 1
1 of 6
ESK-001 Dose Level 4
1 of 6
ESK-001 Dose Level 2
1 of 6
ESK-001 Dose Level 3
1 of 6
Placebo
1 of 6

Experimental Treatment

Non-Treatment Group

210 Total Participants · 6 Treatment Groups

Primary Treatment: ESK-001 Dose Level 5 · Has Placebo Group · Phase 2

ESK-001 Dose Level 5
Drug
Experimental Group · 1 Intervention: ESK-001 · Intervention Types: Drug
ESK-001 Dose Level 1
Drug
Experimental Group · 1 Intervention: ESK-001 · Intervention Types: Drug
ESK-001 Dose Level 4
Drug
Experimental Group · 1 Intervention: ESK-001 · Intervention Types: Drug
ESK-001 Dose Level 2
Drug
Experimental Group · 1 Intervention: ESK-001 · Intervention Types: Drug
ESK-001 Dose Level 3
Drug
Experimental Group · 1 Intervention: ESK-001 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

Alumis IncLead Sponsor
2 Previous Clinical Trials
63 Total Patients Enrolled

Eligibility Criteria

Age 18 - 75 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
California100.0%
What site did they apply to?
Investigator Site #1027100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%